evipedia.ai ← Back

Vitamin K1 for Health & Longevity

Evidence Review created on 08/11/2026 using AI4L / Opus 5

Also known as: Phylloquinone, Phytonadione, Phytomenadione

Motivation

Vitamin K1 (phylloquinone) is the form of vitamin K that plants make, and it is the form most people obtain from food — leafy greens such as kale, spinach, and broccoli are the richest sources. Its best-known job is allowing blood to clot normally. The same chemical step it powers also switches on proteins that help steer calcium into bone and away from artery walls.

Vitamin K was identified in the 1930s through work on a bleeding disease in chicks, and for decades it was treated as a clotting nutrient and nothing more. Interest widened once researchers found proteins that depend on vitamin K in bone, cartilage, and blood vessels, and observed that people with less vitamin K1 in their blood tended to fare worse over long follow-up periods.

This review examines what the evidence shows about vitamin K1 for health and longevity: how it works in the body, what supplementing it has and has not achieved in controlled testing, the risks and drug interactions it carries, and how intake is dosed, sourced, and monitored. Where the evidence is unsettled, the review sets out the competing readings.

Benefits - Risks - Protocol - Conclusion

High-level overviews of vitamin K1 from expert practitioners, commercial health publishers, and narrative academic reviews.

Note on priority platforms: peterattiamd.com mentions vitamin K only in passing inside lipoprotein transcripts; hubermanlab.com’s vitamin K material sits on its excluded AI-generated question-and-answer subdomain; lifespan.io covers menaquinone but has no phylloquinone piece.

Grokipedia

Phytomenadione

Grokipedia’s dedicated page for vitamin K1 under its pharmaceutical name, covering chemical structure, the carboxylation cycle, clinical uses including anticoagulant reversal, and dosing conventions.

Examine

Vitamin K

Examine’s evidence-graded page covers both vitamin K forms, listing studied phylloquinone dose ranges, outcome grades for bone and cardiovascular endpoints, and documented drug interactions.

ConsumerLab

Vitamin K Supplements Review (Including Calcium, Vitamin D, Magnesium & Boron)

Independent laboratory testing of marketed vitamin K products, including cases where measured content fell short of label claims. Full access requires a paid subscription, which is ConsumerLab’s revenue model.

Systematic Reviews

Systematic reviews and meta-analyses covering both the claimed benefits of vitamin K1 and its principal risk, interference with anticoagulant therapy.

Mechanism of Action

Vitamin K1 acts as an enzyme cofactor, not a hormone. It supplies reducing power to gamma-glutamyl carboxylase (GGCX, the enzyme that adds carbon dioxide to selected glutamate residues in target proteins). The product is a gamma-carboxyglutamate (Gla) residue, which binds calcium. Around seventeen human proteins depend on this step: clotting factors II, VII, IX and X in the liver; osteocalcin, which helps anchor calcium in bone; and matrix Gla protein (MGP, the main brake on calcium crystal growth in artery walls and cartilage). Each carboxylation oxidizes vitamin K1 to an epoxide, which vitamin K epoxide reductase complex subunit 1 (VKORC1, the recycling enzyme that warfarin blocks) converts back to the active form, letting a small pool turn over repeatedly.

Pharmacologically, vitamin K1 is highly fat-soluble and needs bile and dietary fat for absorption. Its plasma half-life is short, roughly 1.5–3 hours, and the liver takes it up preferentially, so hepatic clotting-factor carboxylation is served before bone and vessel proteins. Some K1 is stripped of its side chain and re-prenylated by UBIAD1 (the enzyme that attaches the menaquinone tail) into menaquinone-4 (MK-4, a K2 form) in tissues outside the liver. Catabolism runs through CYP4F2 (a liver enzyme that hydroxylates vitamin K), then chain shortening to acid metabolites cleared in bile and urine.

Mechanistic accounts diverge on whether supplemental K1 reaches tissues outside the liver in amounts sufficient to carboxylate MGP; supporters point to falling uncarboxylated MGP after dosing, skeptics to rapid hepatic clearance.

Historical Context & Evolution

Vitamin K1’s original use was purely about stopping bleeding. Henrik Dam described a bleeding disease in chicks fed fat-extracted diets in 1929 and named the missing factor “Koagulationsvitamin” in 1935; Edward Doisy isolated and synthesized phylloquinone, and the two shared the 1943 Nobel Prize. The compound entered practice as an antidote — first for the bleeding disease of newborns, with routine injection at birth adopted in the United States from 1961, and later for reversing the coumarin anticoagulants that had themselves been derived from spoiled sweet clover.

The health-optimization interest arrived from a different direction. In 1974 the carboxylated Gla residue was identified in prothrombin, by 1976 the same residue had been found in osteocalcin, and in 1983 it turned up again in matrix Gla protein — proteins with no clotting role at all. That finding reframed vitamin K as a nutrient acting on bone and vessels, and drove the trials examined in this review.

One historical controversy is worth stating plainly rather than labeling. A 1992 British case-control analysis — comparing children who developed cancer with those who did not — reported an association between intramuscular vitamin K1 at birth and later childhood cancer. Subsequent larger cohort and record-linkage studies did not reproduce it, and pooled analyses found no association; the original authors themselves later reported weaker findings. The episode is best read as a small study whose signal did not survive replication, not as a fabrication, and it left a durable minority of parental refusal that persists today.

Expected Benefits

High 🟩 🟩 🟩

Restored Carboxylation of Vitamin K–Dependent Proteins

Supplemental vitamin K1 converts the inactive, undercarboxylated forms of osteocalcin and matrix Gla protein into their active, calcium-binding forms. This is the vitamin’s direct biochemical action, and every controlled trial measuring it has shown the effect. The ECKO trial raised serum vitamin K1 roughly tenfold at 5 mg daily and lowered undercarboxylated osteocalcin; 1 mg daily for four weeks cut it sharply. Whether this translates into clinical endpoints is the open question.

Magnitude: 1 mg daily for four weeks reduced undercarboxylated osteocalcin from 43.8% to 18.0% of total osteocalcin; 5 mg daily raised circulating vitamin K1 about tenfold.

Correction of Vitamin K–Deficient Coagulopathy (Impaired Blood Clotting)

Where clotting time is prolonged by poor vitamin K status — from fat malabsorption, cholestatic liver disease (impaired bile flow), bariatric surgery, or very low green-vegetable intake — oral or injected vitamin K1 restores clotting factor activity within hours to a day. This is the established therapeutic use of the compound and is not seriously disputed. For a proactive reader it matters mainly as a signal: an unexplained prolonged clotting time points to poor status worth correcting, rather than being a benefit to chase.

Magnitude: Oral vitamin K1 at 1–2.5 mg lowers a supratherapeutic international normalized ratio (INR, a standardized measure of clotting time) below 5 within roughly 24 hours in most recipients.

Medium 🟩 🟩

Slowed Vascular Calcification and Arterial Stiffening ⚠️ Conflicted

Matrix Gla protein needs vitamin K to block calcium deposition in artery walls, and trials have tested whether supplementation slows it. A three-year trial of 500 µg daily in 388 older adults found no overall difference, but among participants at least 85% adherent with existing deposits, progression was 6% lower. A three-year trial pairing 1 mg vitamin K1 with vitamin D and minerals preserved carotid elasticity, though the combination clouds attribution. A hemodialysis trial raised vitamin K status sharply yet changed no calcification measure.

Magnitude: 6% less coronary calcium progression over three years in the adherent subgroup with pre-existing calcification; no difference in the intention-to-treat analysis (counting every participant as originally assigned).

Stabilized Anticoagulation in Warfarin Users with Unexplained Variability ⚠️ Conflicted

Counterintuitively, a small fixed daily dose of vitamin K1 can steady rather than disrupt warfarin control in people whose INR swings unpredictably, by damping day-to-day dietary variation. A randomized trial of 150 µg daily improved both time in the target range and INR variability. A Cochrane review judged the pooled evidence too thin to endorse the practice routinely. This benefit exists only under prescriber supervision.

Magnitude: Time within the target INR range rose 28% with 150 µg daily versus 15% with placebo, and the standard deviation of the INR (a measure of how widely it swings) fell 0.24 versus 0.11.

Low 🟩

Reduced Clinical Fracture Incidence ⚠️ Conflicted

Randomized data are inconsistent. ECKO recorded fewer clinical fractures on 5 mg daily despite no bone-density benefit, and the updated meta-analysis found a reduction that lost significance once high-bias trials were excluded.

Magnitude: 9 versus 20 clinical fractures over 2–4 years in ECKO; pooled odds ratio (OR, the ratio of the odds of an event between groups) 0.72, 95% confidence interval (CI) 0.55–0.95, weakening to 0.76 (0.58–1.01) in low-bias trials.

Improved Post-Load Glucose Handling

Thirty-six months of 500 µg daily lowered insulin resistance in older men but not women, and 1 mg daily for four weeks improved two-hour glucose and insulin sensitivity in prediabetic women. Trials are small and measure laboratory values rather than diagnoses.

Magnitude: Two-hour glucose 7.32 versus 8.62 mmol/L and two-hour insulin 80.3 versus 112.4 µIU/mL after four weeks at 1 mg daily.

Lower All-Cause Mortality Associated with Higher Vitamin K1 Status

Consistent across large cohorts, but entirely observational — no supplementation trial has ever used death as an endpoint, and green-vegetable intake tracks many other healthy behaviors. Circulating and dietary measures agree in direction.

Magnitude: Hazard ratio (HR, the relative rate of events over time) 1.19 (95% CI 1.03–1.38) for plasma phylloquinone ≤0.5 nmol/L versus >1.0 nmol/L; HR 0.76 (0.72–0.79) for the highest versus lowest intake quintile (fifth of the cohort).

Speculative 🟨

Preserved Cognitive Function

Based on observational association only: dietary vitamin K intake, predominantly K1, tracked with better cognitive function in an older Mediterranean population. No supplementation trial has tested a cognitive outcome.

Reduced Cancer Incidence

Rests on an underpowered secondary count in ECKO — three cancers versus twelve — and mixed cohort data. No trial was designed to test this; the finding is hypothesis-generating only.

Slowed Knee Osteoarthritis Progression

Mechanistic and observational only: mild vitamin K deficiency preceded new knee osteoarthritis visible on X-ray. No completed randomized trial exists; two are running.

Benefit-Modifying Factors

  • Genetic variation in transport and catabolism: A genome-wide meta-analysis linked circulating phylloquinone to CYP4F2 (which degrades vitamin K) and the APOA1/C3/A4/A5 lipoprotein cluster (which carries it in blood). Carriers of faster-catabolism variants reach lower levels at the same intake.

  • Baseline vitamin K status: Benefit concentrates in those starting low. In trials, people with already-carboxylated osteocalcin and matrix Gla protein have little headroom, which is one reason well-nourished cohorts show null results on hard endpoints.

  • Sex-based differences: The 36-month insulin-resistance benefit appeared in men only, with a significant sex-by-treatment interaction. Bone trials have been run almost exclusively in postmenopausal women, so male skeletal response is largely uncharacterized.

  • Pre-existing health conditions: Fat malabsorption, cholestatic liver disease, celiac disease, inflammatory bowel disease, and prior bariatric surgery all lower absorption and enlarge the potential gain. Chronic kidney disease raises uncarboxylated matrix Gla protein markedly.

  • Age: Uncarboxylated matrix Gla protein rises with age, so older adults in the target range typically have more room to improve. Vascular endpoints in trials required three years to move, favoring earlier and longer use.

  • Dietary fat and food matrix: Phylloquinone bound in plant chloroplast membranes is absorbed far less efficiently than the free form in softgels. Co-ingested fat raises absorption of both, making a fat-containing meal a genuine modifier of effect.

Potential Risks & Side Effects

High 🟥 🟥 🟥

Antagonism of Warfarin and Other Vitamin K Antagonists

Vitamin K1 directly reverses the drug class that works by blocking vitamin K recycling, so added intake lowers the INR and can drop a patient below the protective range. The consequence is clotting: stroke in atrial fibrillation (an irregular heart rhythm), clot formation on a mechanical heart valve, or recurrence after venous thromboembolism (a clot in a deep vein or the lung). The effect is dose-dependent and begins within a day. A systematic review argues that stable intake matters more than absolute amount.

Magnitude: 1–2.5 mg oral vitamin K1 typically lowers a supratherapeutic INR below 5 within 24 hours; even 100–150 µg daily measurably shifts warfarin dose requirements.

Medium 🟥 🟥

Anaphylactoid Reactions to Intravenous Phytonadione

Anaphylactoid (anaphylaxis-like) reactions — sudden blood-pressure collapse, airway narrowing, cardiac arrest — are documented after intravenous vitamin K1 and are attributed largely to the polyethoxylated castor oil solubilizer rather than the vitamin. A five-year retrospective review put the incidence at roughly three per ten thousand doses. This risk belongs to the injected route only; oral phylloquinone has no comparable signal, which is one reason oral dosing is preferred whenever the clinical situation allows.

Magnitude: Approximately 3 anaphylactic reactions per 10,000 intravenous doses (2 events in 6,572 doses; 95% CI 0.04–11 per 10,000).

Low 🟥

Gastrointestinal Intolerance

Nausea, abdominal discomfort, and loose stools are the commonly reported oral complaints, generally mild and dose-related. In ECKO, four years of 5 mg daily produced no significant excess of adverse effects or quality-of-life decrement versus placebo.

Magnitude: No statistically significant excess over placebo across 2–4 years at 5 mg daily; individual reports are sporadic rather than quantified as an incidence rate.

Cutaneous Reactions at Injection Sites

Intramuscular or subcutaneous phytonadione can provoke delayed local reactions: itchy, eczema-like patches, or rarely a firm hardened plaque persisting for months. These are hypersensitivity phenomena, not toxicity, and do not occur with oral dosing.

Magnitude: Risk rises with repeated injected dosing and is absent with oral use; the literature reports these only as case series and gives no incidence figure.

Speculative 🟨

Prothrombotic Shift in Thrombophilia

Fully carboxylated clotting factors are the intended effect, but whether high-dose K1 raises clot risk in thrombophilia (an inherited tendency to clot) is untested. No trial has reported excess clotting; the concern is mechanistic.

Childhood Cancer After Neonatal Injection ⚠️ Conflicted

A 1992 case-control report suggested an association that later, larger cohort and record-linkage studies did not reproduce. The claim is unsupported by replication rather than disproven outright, and remains a live concern for some parents.

Risk-Modifying Factors

  • VKORC1 and CYP2C9 variants: Carriers of VKORC1 -1639G>A or reduced-function CYP2C9 alleles (the enzyme clearing warfarin) need lower warfarin doses and are proportionally more sensitive to added vitamin K1, amplifying the anticoagulation risk.

  • Baseline INR and liver panel: A borderline-high INR or cholestatic liver enzymes signal both greater deficiency and greater sensitivity to correction. Testing before starting distinguishes genuine deficiency from an anticoagulant effect that must not be blunted.

  • Sex-based differences: No sex difference in adverse effects has been demonstrated in the randomized record. Bone and vascular trials enrolled predominantly women, so male-specific safety data are correspondingly sparse rather than reassuring.

  • Pre-existing health conditions: Mechanical heart valves, recent venous thromboembolism, and atrial fibrillation on warfarin convert vitamin K1 from benign to hazardous. Cholestatic liver disease raises both baseline deficiency and reaction risk from parenteral dosing.

  • Age: Older adults are far likelier to be on an anticoagulant and to have reduced renal clearance of co-prescribed drugs, so the interaction risk rises with age even though the compound’s own toxicity does not.

Key Interactions & Contraindications

  • Vitamin K antagonists (warfarin, acenocoumarol, phenprocoumon): Absolute caution. Vitamin K1 reverses their effect, risking stroke or valve thrombosis. Mitigation: keep intake fixed rather than eliminated, and recheck INR weekly for 4–6 weeks after any change.

  • Lipase inhibitors (orlistat, prescription and over-the-counter): Caution. Blocks fat absorption and with it phylloquinone, risking deficiency and unstable anticoagulation. Mitigation: take vitamin K1 at least 2 hours before or 4 hours after orlistat.

  • Bile acid sequestrants (cholestyramine, colestipol, colesevelam): Caution. Bind vitamin K1 in the gut and reduce uptake, potentially causing deficiency bleeding over months. Mitigation: separate dosing by 4 hours and monitor INR annually.

  • Enzyme-inducing anticonvulsants (phenytoin, carbamazepine, phenobarbital): Monitor. Accelerate vitamin K catabolism, lowering status. Mitigation: dietary-range supplementation and periodic INR checks; relevant particularly in pregnancy.

  • Mineral oil and other over-the-counter fat-soluble laxatives: Caution. Chronic use traps fat-soluble vitamins in the intestinal lumen, causing gradual depletion. Mitigation: avoid chronic use, or separate dosing by several hours.

  • High-dose vitamin E (above roughly 800 IU, or international units, daily): Monitor. Tocopherol quinone metabolites antagonize vitamin K–dependent carboxylation and can prolong clotting time. Mitigation: keep vitamin E within 200–400 IU daily if supplementing vitamin K1.

  • Vitamin K2 (menaquinone-4, menaquinone-7): Additive rather than adverse. Both feed the same carboxylation cycle, so combined use compounds any anticoagulant antagonism. Mitigation: count total vitamin K, not each form separately, when on warfarin.

  • Vitamin D3 and calcium: Additive and generally intended. Vitamin D raises matrix Gla protein expression that vitamin K1 then activates; the pairing was used in the carotid-elasticity trial. No mitigation needed absent hypercalcemia (high blood calcium).

  • Antiplatelet and anticoagulant supplements (fish oil, garlic, ginkgo, nattokinase): Monitor. These raise bleeding tendency while vitamin K1 opposes it, obscuring the net effect on clotting. Mitigation: stagger introductions and recheck clotting time.

  • Direct oral anticoagulants (apixaban, rivaroxaban, dabigatran): No interaction. These act downstream of vitamin K, so phylloquinone neither reverses nor potentiates them — a relevant contrast when weighing anticoagulant choice.

Populations who should avoid Vitamin K1:

  • Anyone taking a vitamin K antagonist without prescriber supervision, particularly with a mechanical mitral valve (target INR 2.5–3.5) or venous thromboembolism within the past 3 months
  • Individuals with a documented prior anaphylactoid reaction to parenteral phytonadione (applies to injected forms; oral use may still be appropriate)
  • Individuals with known hypersensitivity to phylloquinone or to polyethoxylated castor oil in injectable preparations

Risk Mitigation Strategies

  • Anticoagulant status established first: Screening for warfarin, acenocoumarol, and phenprocoumon use precedes any protocol; this is the only interaction that converts a low-risk nutrient into a stroke or valve-thrombosis hazard.

  • Constant intake rather than avoidance: For those on warfarin under supervision, a fixed 100–150 µg daily reduces INR swings; erratic intake, not intake itself, drives instability and bleeding or clotting events.

  • Weekly INR rechecks for 4–6 weeks after any change: These detect the dose-dependent drop in anticoagulant effect early, before the INR falls below the protective range and thrombotic risk rises.

  • Oral route over injection: Oral phylloquinone carries no anaphylactoid signal, unlike intravenous phytonadione at roughly 3 reactions per 10,000 doses; injection is reserved for clinical settings where speed is required.

  • Separation from fat-absorption blockers: Dosing at least 2 hours before or 4 hours after orlistat, and 4 hours from bile acid sequestrants, prevents the deficiency those drugs otherwise produce.

  • Dietary-range starting dose: Protocols beginning at 100–500 µg daily rather than 5 mg cover the documented carboxylation benefits while minimizing gastrointestinal intolerance and the magnitude of any anticoagulant interaction.

  • Concurrent vitamin E cap: Supplemental vitamin E at or below 400 IU daily avoids the higher intakes that antagonize vitamin K–dependent carboxylation and can prolong clotting time.

Therapeutic Protocol

  • Standard dose range: Practitioners commonly use 100–500 µg daily of phylloquinone, the range that normalized carboxylation markers in the three-year trials. 1 mg daily is used where vascular markers are the target.

  • High-dose approach: The ECKO protocol used 5 mg daily for 2–4 years, available as prescription phytonadione tablets. It produced no bone-density gain, so higher dosing is not obviously better.

  • Competing approach — K1 plus K2: The Maastricht group around Cees Vermeer argues extrahepatic proteins are better served by menaquinone-7, and pairs 100–200 µg MK-7 with dietary K1. Neither approach has beaten the other head-to-head.

  • Competing approach — food first: Chris Kresser and others favor 100 µg or more from greens and grass-fed dairy plus fat, on the reasoning that supplementation has not reproduced the observational benefits of high-vitamin-K diets.

  • Best time of day: With the largest fat-containing meal, typically the evening meal. Absorption depends on bile flow and co-ingested fat; timing relative to circadian rhythm has no demonstrated effect.

  • Half-life and dose splitting: Plasma half-life is roughly 1.5–3 hours, so a single daily dose produces a sharp peak and trough. Splitting into two doses is plausible for steadier exposure but untested against once-daily.

  • Genetic considerations: CYP4F2 and APOE (a gene shaping fat transport in blood) variants shift circulating phylloquinone at identical intake; VKORC1 and CYP2C9 genotypes matter only on warfarin. Routine genotyping is not standard practice.

  • Sex-based differences: The insulin-resistance benefit was confined to men over 36 months. Fracture and bone-density data derive almost entirely from postmenopausal women, so protocol evidence is sex-asymmetric.

  • Age-related considerations: Adults over 65 start with higher uncarboxylated matrix Gla protein and more headroom, but also higher anticoagulant prevalence. Longer duration matters more than higher dose at any age.

  • Baseline biomarkers: Plasma phylloquinone below 0.5 nmol/L, or elevated uncarboxylated markers, identifies who has room to benefit. Well-carboxylated individuals have little left to gain.

  • Pre-existing conditions: Fat malabsorption, cholestasis, celiac disease, and post-bariatric anatomy warrant higher doses or water-miscible formulations, since standard softgels may not be absorbed adequately.

  • Adequate intake reference: The US National Academies — a non-commercial body with no product revenue — set adequate intake at 120 µg daily for men and 90 µg for women, a figure based on clotting sufficiency alone.

Discontinuation & Cycling

  • Lifelong versus short-term: Framed as ongoing nutritional support rather than a course of treatment. Vascular and skeletal endpoints in trials required three years or more to shift, so short courses have no demonstrated value.

  • Withdrawal effects: None documented. Circulating phylloquinone falls within days of stopping given the short half-life, and carboxylation markers drift back toward baseline over weeks without rebound.

  • Tapering: Not required for the general user. The exception is anyone on warfarin, where abrupt discontinuation raises the INR and requires prescriber-supervised dose re-titration with weekly checks.

  • Cycling: No rationale. No tolerance, receptor downregulation, or diminishing response has been described; the carboxylation cycle regenerates the cofactor continuously rather than depleting a signaling pathway.

Sourcing and Quality

  • Form to look for: Natural trans-phylloquinone. Synthetic material can contain the biologically inactive cis isomer; reputable labels state trans content, and cis-heavy product delivers less active vitamin than the label implies.

  • Label accuracy: ConsumerLab has repeatedly found vitamin K products containing less than the labeled amount, including bone-health formulas. Third-party verification matters more here than for most nutrients.

  • Third-party testing: USP Verified, NSF Certified for Sport, and ConsumerLab Approved marks confirm identity and content. Certificates of analysis from the manufacturer alone are weaker evidence.

  • Delivery format: Oil-filled softgels outperform dry tablets, since phylloquinone absorption depends on lipid co-delivery. Emulsified or micellar liquids are the practical option for people with fat malabsorption.

  • Reputable suppliers: Thorne, Pure Encapsulations, Life Extension, NOW Foods, and Jarrow Formulas all market tested phylloquinone; Life Extension is also a publisher cited in this review, which is a commercial overlap worth noting.

  • Prescription and compounded options: 5 mg phytonadione tablets are a prescription product in the United States. Compounding pharmacies can supply non-standard strengths where a documented malabsorption problem justifies them.

Practical Considerations

  • Time to effect: Carboxylation markers shift within 2–4 weeks. Vascular and skeletal endpoints in the randomized record needed three years, so judging the intervention on months of use is a category error.

  • Common pitfall — taking it without fat: Phylloquinone absorption depends on bile and dietary lipid. A softgel on an empty stomach delivers a fraction of the labeled dose and undermines the whole protocol.

  • Common pitfall — expecting K2’s results: The cardiovascular literature that drives most enthusiasm is largely menaquinone data. K1 trials on hard endpoints are fewer and weaker, and the two forms are not interchangeable.

  • Common pitfall — silent warfarin interaction: People starting a bone or heart supplement regimen often do not register that it contains vitamin K, then see an unexplained INR drop weeks later.

  • Regulatory status: In the United States phylloquinone is a dietary supplement below prescription strength; 5 mg phytonadione is prescription-only. No tolerable upper intake level has been set, reflecting absent data rather than proven safety at any dose.

  • Cost and accessibility: Inexpensive and widely available — typically a few dollars monthly, against several times more for menaquinone-7. Neither form is reimbursed by insurers or national health systems, so no institutional payer incentive shapes guidelines or research funding toward either.

Interaction with Foundational Habits

  • Sleep: No direct interaction. Phylloquinone has no demonstrated effect on sleep architecture, melatonin, or circadian timing in either direction, and no trial has reported sleep disturbance. The only practical link is indirect: dosing with the evening meal, chosen for fat content, has no sleep consequence and needs no separation from bedtime.

  • Nutrition: Strongly potentiating and the single most important habit interaction. Absorption requires bile and dietary fat, so phylloquinone is dosed with a meal containing at least 10–15 g of fat. Leafy greens supply the vitamin bound inside plant cell structures, absorbed far less efficiently than softgel phylloquinone; olive oil on salad narrows that gap.

  • Exercise: No direct interaction; no blunting of hypertrophy or endurance adaptation has been described, unlike high-dose antioxidants. The plausible indirect link runs through bone: mechanical loading drives osteocalcin production, and vitamin K1 determines what fraction is carboxylated, so resistance and impact training and vitamin K1 act on the same protein from different ends.

  • Stress management: No direct interaction with cortisol or the stress response has been demonstrated. The indirect route is that sustained cortisol elevation suppresses osteocalcin production and accelerates bone loss, which reduces the substrate vitamin K1 acts on. Stress control therefore supports, but does not modify, the vitamin’s mechanism.

Monitoring Protocol & Defining Success

Before starting, the useful baseline is narrower than it first appears. Two questions decide whether vitamin K1 is worth taking: is status actually low, and is there an anticoagulant in play. A plasma phylloquinone level, a functional carboxylation marker, and a clotting time answer both. Adding a coronary calcium score and bone density is worthwhile for anyone whose interest is vascular or skeletal, because those measures move slowly and cannot be inferred from blood work.

For ongoing monitoring, recheck the clotting time at 4 weeks, then the carboxylation markers at 3 months once a stable dose is reached. After that, plasma phylloquinone and functional markers every 6–12 months are sufficient. Structural measures — calcium score and bone density — change too slowly to justify repeating more often than every 2–3 years.

Biomarker Optimal Functional Range Why Measure It? Context/Notes
Plasma phylloquinone (vitamin K1) >1.0 nmol/L Direct measure of circulating supply Fasting sample required; levels track recent intake and rise sharply after a dose, so sampling precedes the day’s dose
Dephosphorylated-uncarboxylated matrix Gla protein (dp-ucMGP) <400 pmol/L Functional marker of vascular vitamin K sufficiency The vessel-wall counterpart to osteocalcin; rises in chronic kidney disease independent of intake
Undercarboxylated osteocalcin (%ucOC) <20% of total osteocalcin Functional marker of skeletal vitamin K sufficiency Best paired with total osteocalcin, since the percentage is the informative figure; fasting sample preferred
Prothrombin time / INR 0.9–1.1 (not on an anticoagulant) Detects frank deficiency and flags anticoagulant interference INR = international normalized ratio, the standardized clotting-time measure; a value below range on warfarin signals antagonism
PIVKA-II Below the assay’s detection cutoff Earliest sensitive marker of hepatic vitamin K deficiency PIVKA-II = protein induced by vitamin K absence-II, the uncarboxylated form of prothrombin; more sensitive than INR
25-hydroxyvitamin D 40–60 ng/mL Vitamin D drives production of the proteins vitamin K1 activates Conventional labs often call 30 ng/mL sufficient; functional practitioners target higher. Fasting not required
Coronary artery calcium score 0, or no progression from personal baseline Structural endpoint the vascular hypothesis predicts No universal target above zero exists; change is tracked against the individual’s own prior scan, with repeat scans no sooner than 2–3 years
Bone mineral density (DEXA T-score) ≥ -1.0, or no decline from personal baseline Structural endpoint for the skeletal hypothesis DEXA = dual-energy X-ray absorptiometry. Trials showed no density gain from vitamin K1, so stability rather than improvement is the realistic marker

Qualitative markers worth tracking alongside the labs:

  • Ease of bruising and duration of bleeding from minor cuts, which reflect clotting adequacy more immediately than any scheduled test
  • Frequency of nocturnal leg cramps, which some users report improving and which ConsumerLab notes as a possible effect
  • Gum bleeding when brushing or flossing, an early and easily observed sign of poor clotting-factor carboxylation
  • Digestive tolerance in the first weeks, since nausea or loose stools are the usual reason people abandon the protocol

Emerging Research

  • Knee osteoarthritis structural trial: NCT06385275 at Boston University, a Phase 1/2 randomized trial in 55 participants, measures change in uncarboxylated matrix Gla protein and phylloquinone levels. It is the larger of two interventional tests of the osteoarthritis association.

  • Osteoarthritis function trial: NCT05505552 at Tufts University, 37 participants, examines vitamin K effects on lower-extremity function with plasma uncarboxylated matrix Gla protein as the primary endpoint. Small size limits it to signal detection.

  • Oncology combination trial: NCT04752813, a Phase 2 trial of BPM31510 with vitamin K1 in 50 patients with newly diagnosed glioblastoma (an aggressive brain cancer), uses progression-free survival as its endpoint. Here vitamin K1 serves a pharmacological role, not a nutritional one.

  • Bioavailability trial: NCT06921018 at the University of Copenhagen compares micronutrient status, vitamin K foremost, between plant-based and conventional Danish diets in 20 participants. It targets the food-matrix absorption question directly.

  • Evidence that could weaken the case: A randomized hemodialysis trial by Holden et al., 2023, cut dephosphorylated-uncarboxylated matrix Gla protein by 86% yet produced no difference in coronary calcification progression, extending the pattern of null results on hard vascular endpoints in high-risk populations.

  • Evidence that could strengthen it: A dose-response meta-analysis by Haghighat et al., 2025, reports dietary vitamin K intake and fracture risk interacting with vitamin D status, suggesting past null trials may have tested the wrong populations.

  • Molecular response signatures: An epigenome-wide association study of phylloquinone supplementation by Westerman et al., 2020 — a scan of chemical marks on DNA — found a signature distinguishing responders, a route toward identifying who benefits rather than dosing everyone alike.

  • Unresolved question — form equivalence: Whether menaquinone-7’s longer half-life produces better extrahepatic outcomes than phylloquinone remains untested head-to-head. Cohort data from Bellinge et al., 2021, show similar inverse associations for both forms despite different food sources.

Conclusion

Vitamin K1 is the plant form of vitamin K, the one that arrives in the diet mainly through leafy greens. Its role in blood clotting is settled and beyond dispute, and supplementing it reliably switches on the calcium-handling proteins in bone and artery walls that depend on it. That biochemical effect is the strongest thing that can be said for it, and it is genuinely strong.

What remains unsettled is whether that change produces the outcomes people take it for. People with more vitamin K1 in their blood and diet consistently live longer and have fewer heart events in large observational studies, but the supplement trials have been smaller, shorter, and mostly negative on the outcomes that matter — bone density, fractures, artery calcium. The one positive artery finding came only from the participants who actually took it consistently, not from the trial as a whole.

The safety picture is unusually favorable. Oral vitamin K1 has no established toxic dose, and side effects in multi-year trials were indistinguishable from placebo. The single serious hazard is that it directly cancels the older blood thinners, and that interaction is large enough to dominate the risk picture for anyone taking them.

Two commercial notes belong here: much of the accessible writing on vitamin K comes from companies selling supplements or subscriptions, and the more expensive K2 form has an industry behind it that plain vitamin K1 lacks.

Top - Benefits - Risks - Protocol